Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Roubaix – page 94

1 745 clinical trials in Roubaix, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Roubaix at a glance
1 745
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 745 trials in Roubaix

Open in trial search

Hormone-refractory prostate cancer+1

Not recruiting

Study of PF-06821497 with Enzalutamide for Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Pfizer Inc.

Plasma cell myeloma refractory

Not recruiting

Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Kite Pharma Inc.

Chronic obstructive pulmonary disease

Not recruiting

Study of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Metastatic malignant melanoma

Not recruiting

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Amgen Inc.

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Transitional cell carcinoma

Not recruiting

Study on the Effects of 3 vs 6 Cycles of Platinum-based Chemotherapy and Avelumab in Patients with Advanced Urothelial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Queen Mary University Of London

Cardiac amyloidosis

Not recruiting

Study of Patisiran for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Patisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Alcoholism

Not recruiting

Study on Cannabidiol for Reducing Alcohol Consumption in Patients with Alcohol Use Disorder

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cannabidiol
  • Sponsor:Centre Hospitalier Le Vinatier

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Chronic graft versus host disease

Not recruiting

Study of Axatilimab for Patients with Chronic Graft Versus Host Disease After Two Prior Treatments

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Syndax Pharmaceuticals Inc.

Prostate cancer metastatic

Not recruiting

Study of Debio 4228 for Patients with Advanced or Metastatic Prostate Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix
  • Sponsor:Debiopharm International S.A.

Hepatic cirrhosis

Not recruiting

Study of Resmetirom in Patients with Well-compensated Non-alcoholic Steatohepatitis (NASH) Cirrhosis to Evaluate Effects on Liver Health

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Resmetirom
  • Sponsor:Madrigal Pharmaceuticals Inc.

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Roubaix

What the registry says about research in the country

01 Hematologic Oncology

Research focusing on innovative treatments for Multiple Myeloma and various forms of leukemia, including comparative studies of novel therapeutic combinations and traditional approaches.

  • Multiple Myeloma therapies
  • Acute Myeloid Leukemia treatments
  • Myeloproliferative disorders

Studies evaluating treatment effectiveness in newly diagnosed patients and those with advanced disease stages.

02 Neurological Disorders

Innovative research exploring potential treatments for Alzheimer's disease, including studies on caffeine's effects on cognitive function in early-to-moderate stage patients.

  • Cognitive decline prevention
  • Novel therapeutic approaches
  • Disease progression monitoring

Focus on non-pharmacological interventions and their impact on disease progression.

03 Respiratory Medicine

Clinical investigations into severe asthma management and pulmonary infections, including studies on treatment optimization and novel therapeutic approaches.

  • Severe allergic asthma control
  • Mycobacterium avium complex treatment
  • Medication withdrawal studies

Evaluation of long-term treatment strategies and comparative medication studies.

04 Cardiovascular and Renal Studies

Research examining hypertension management in patients with chronic kidney disease, along with studies on thrombo-embolic complications prevention.

  • Blood pressure management
  • Kidney disease progression
  • Cardiovascular risk reduction

Focus on optimizing treatment strategies for complex cardiovascular conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.